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S U M M A R Y
Background: Co-infection with hepatitis B virus (HBV) and HIV is common in China; however, the impact
of HBV on long-term antiretroviral therapy (ART) outcomes has not been fully characterized.
Methods: Patients were classiﬁed as being HIV mono-infected (hepatitis B surface antigen (HBsAg)-
negative) or HIV/HBV co-infected (HBsAg-positive). The effects of HBV on HIV virological response,
changes in CD4 cell counts, hepatotoxicity, and mortality among Chinese patients receiving ART were
evaluated.
Results: The HIV/HBV co-infection rate in our cohort was 9.9% (354/3562). Five hundred and ﬁfty HIV
mono-infected and 78 HIV/HBV co-infected individuals fulﬁlled the inclusion criteria. HIV/HBV co-
infected individuals were less likely to achieve HIV-RNA suppression and a CD4 increase than HIV mono-
infected individuals at 48 months post-ART. Greater hepatotoxicity and a more rapid occurrence of death
were observed in HIV/HBV co-infected subjects. HBV-related mortality accounted for 84.2% (16/19) of
the total deaths in HIV/HBV co-infected subjects.
Conclusions: HBV co-infection can affect late immunological and virological responses to ART and
increase the risk of hepatotoxicity. Mortality due to liver disease was high among HIV/HBV co-infected
individuals in this study, despite HBV-active ART. As long as HIV/HBV co-infected persons need anti-HBV
therapy, they should be recommended ART that includes agents with activity against both HIV and HBV,
regardless of the CD4 cell count level.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In China, approximately 700 000 people are infected with HIV in
a population of more than 1.3 billion.1 China is a country with one
of the highest prevalence rates for hepatitis B surface antigen
(HBsAg) seropositivity in the population, with a reported preva-
lence of 7.18% in 2006.2 Chronic hepatitis B (CHB) occurs in about
10% of HIV-infected individuals,3 and it is important to understand
the impact of hepatitis B virus (HBV) infection on HIV-RNA
suppression, CD4 recovery, and hepatotoxicity during antiretrovi-
ral therapy (ART).
Several studies of HIV/HBV co-infected individuals have
examined the short-term response to ART.4–7 However, the impact
of CHB on HIV treatment outcomes remains uncertain because of
inconsistent reports.5,8–10 It is unclear whether CHB affects the rate
and durability of HIV-RNA suppression and increases in CD4 cell* Corresponding author.
E-mail address: znact0@126.com (X. Gui).
http://dx.doi.org/10.1016/j.ijid.2014.07.018
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).counts during ART, especially in China. Thus, we evaluated the
impact of CHB on the outcomes of HIV virological response, CD4
recovery, hepatotoxicity, and mortality among patients at a
Chinese ART center.
2. Patients and methods
2.1. Patients
The study included patients from a single center and all patients
were screened for HBsAg and hepatitis C virus antibodies (anti-
HCV). Patients included in this study fulﬁlled the following criteria:
(1) initiated ART between January 2004 and December 2011; (2)
received follow-up prospectively until May 2013 or for a maximum
of 60 months; (3) had pre-ART serum samples available for testing;
(4) had a minimum of 12 months of follow-up on ART; (5) had
results of at least three follow-up laboratory tests available; (6)
were negative for anti-HCV; and (7) had not received anti-HBV
therapy before ART and/or during ART other than lamivudine
(3TC).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(WHO)12 guidelines, the initiation and monitoring of ART was
based on clinical and immunological parameters. Individuals with
or without HBV received a regimen of stavudine (d4T)/zidovudine
(AZT), 3TC, and nevirapine (NVP)/efavirenz (EFV). Liver function
was tested at baseline, at weeks 2 and 6, and then every 3 months.
CD4 cell counts were determined at baseline, every 3 months for
the ﬁrst year, and then every 6–12 months. The HIV-RNA level was
determined at baseline and then yearly.
This study was approved by the ethics committee of Zhongnan
Hospital of Wuhan University. Informed consent was obtained
from all patients on the collection of demographic data and plasma
samples. All experiments were performed in accordance with the
ethical standards of the Declaration of Helsinki.
2.2. Laboratory measurements
HBsAg and anti-HCV were tested with a third-generation
enzyme immunoassay (EIA) (Shanghai Kehua Biology Company,
China). Real-time PCR kits (Shanghai Kehua Biology Company)
were used to test HBV-DNA levels; the detection limit was
500 copies/ml. HIV viral load was determined using NucliSens Easy
Q HIV-1 v2.0 (bioMe´rieux, Iyon, France), with a limit of detection of
20 copies/ml. The CD4+ T cell count was determined by ﬂow
cytometry (Beckman Coulter Epics XL; Beckman Coulter, Inc., Los
Angeles, USA). Liver function was assessed using an automatic
biochemical analyzer manufactured by Rili Company (Tokyo,
Japan).
2.3. Statistical analysis
Baseline characteristics were summarized with the median and
interquartile range (IQR) for continuous variables and the
proportion for categorical variables. The Chi-square test or Fisher’s
exact test was used for categorical variables. For measurement
data, normal distribution of the measurement data was tested ﬁrst.
If the result was of non-normal distribution, the Wilcoxon test was
used for statistical calculations. If the result was of normal
distribution, t-tests were used. A time to event analysis was
performed using Kaplan–Meier survival curves. All tests wereFigure 1. Flow chart of the study subjects (HBsAg, hepatitis B virus surface antwo-sided and a p-value of <0.05 was taken as signiﬁcant. Analyses
were performed using SPSS for Windows version 13.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Patient demographic data
A total of 3562 newly diagnosed HIV-positive patients were
screened routinely for HBsAg and anti-HCV antibody; 354 were
HBsAg-positive. In accordance with the inclusion criteria of this
study, data from 78 HIV/HBV co-infected patients and 550 HIV
mono-infected patients were analyzed (Figure 1).
3.2. Baseline characteristics
Table 1 summarizes the demographic and clinical character-
istics of the patient population. Of note, the median liver enzymes
at baseline in the HIV/HBV co-infected group were higher
compared to the HIV mono-infected group (p = 0.0001).
3.3. Risk factors associated with ART effect
Multivariate logistic regression identiﬁed HBV co-infection (p =
0.001), baseline CD4 cell count <200 cells/mm3 (p = 0.021),
baseline HIV-RNA >5000 copies/ml (p = 0.027), elevated liver
enzymes (p = 0.031), clinical cirrhosis (p = 0.023), and side effect
related to ART (p = 0.014) as independent risk factors related to ART
effect (Table 2).
3.4. CD4 cell count recovery
Similar CD4 cell count levels were detected in HIV/HBV co-
infected subjects and in HIV mono-infected subjects during
36 months post-ART (Table 3). However, the median CD4+ cell
count was lower in the HIV/HBV co-infected subjects compared to
the HIV mono-infected subjects at 36–48 months (280 cells/ml vs.
333 cells/ml; p = 0.041) and 49–60 months (304 cells/ml vs.
363 cells/ml; p = 0.037).tigen; anti-HCV, hepatitis C virus antibodies; OI, opportunistic infection).
Table 1
Baseline characteristics of the study population
Characteristic HIV mono-infected
(n = 550)
HIV/HBV co-infected
(n = 78)
p-Value
At treatment initiation
Age, years, median (IQR) 45 (26–56) 44 (23–55) 0.268
Male, n (%) 289 (52.5) 41 (52.6) 0.998
HIV transmission route, n (%)
Heterosexual contact 358 (65.1) 49 (62.8) 0.694
Unsafe blood transfusion 85 (15.5) 13 (16.7) 0.783
Commercial plasma donation 61 (11.1) 9 (11.5) 0.906
Homosexual contact 25 (4.5) 4 (5.1) 0.818
Injection drug use 21 (3.8) 3 (3.8) 0.990
Follow-up time between diagnosis and start of ART, months, median (IQR) 3.0 (1–8.8) 3.0 (1–9.1) 0.990
CD4 cell count when diagnosed with HIV infection, 106/l, median (IQR) 103 (50–270) 127 (61–265) 0.190
Nadir CD4 cell count, 106/l, median (IQR) 100 (36–252) 108 (30–240) 0.192
HIV-RNA level, log10 copies/ml, median (IQR) 4.5 (3.8–5.0) 4.5 (3.9–4.7) 0.872
AIDS-deﬁning events, n (%) 247 (44.9) 36 (46.2) 0.836
Clinical cirrhosis, n (%) 0 (0) 2 (2.6) 0.0001
Liver enzymes, U/l, median (IQR)
ALT 30 (21–47) 63 (40–92) 0.0001
AST 30 (23–41) 47 (33–64) 0.0001
Serum HBV-DNA positive rate, n (%) - 36 (46.2) -
Serum HBeAg positive rate, n (%) - 10 (12.8) -
Initial treatment regimen, n (%)
AZT or d4T, 3TC, and NVP 458 (83.3) 58 (74.4) 0.054
AZT or d4T, 3TC, and EFV 92 (16.7) 20 (25.6) -
AZT, 3TC, and NVP or EFV 237 (43.1) 34 (43.6) 0.934
d4T, 3TC, and NVP or EFV 313 (56.9) 44 (56.4) -
HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; IQR, interquartile range; ART, antiretroviral therapy; AIDS, acquired immunodeﬁciency syndrome; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B virus e antigen; AZT, zidovudine; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz.
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Similar HIV-RNA levels were detected in HIV/HBV co-infected
and HIV mono-infected subjects during 36 months post-ART
(Table 4). However, the proportion of patients with detectable
HIV-RNA was higher in HIV/HBV co-infected subjects after
receiving ART for 37–48 months (p = 0.002) and 49–60 months
(p = 0.005).
The proportions of second-line ART usage were 10.9%
(60/550) in HIV mono-infected patients and 12.8% (10/78) in
HIV/HBV co-infected patients. All second-line regimens in this
study comprised tenofovir (TDF)–3TC–lopinavir/ritonavir
(LPV/r).
3.6. Hepatotoxicity and other side effects
During the observation period, the proportion of patients with
hepatotoxicity was greater in those with HIV/HBV co-infection
than in those with HIV mono-infection (Table 5). Among the
patients using NVP who experienced hepatotoxicity, 30% were
switched to EFV.Table 2
Risk factors associated with ART effect
Related factors Univariate analysis 
OR (95% CI) 
Age >45 years 0.978 (0.631–1.223) 
Male 1.926 (0.741–2.014) 
HIV acquisition route 4  109 (0–1) 
HBV co-infection 1.547 (1.168–1.987) 
Baseline CD4 <200 cells/ml 2.783 (1.474–4.236) 
Baseline HIV-RNA >5000 copies/ml 2.128 (1.323–3.201) 
Elevated liver enzymes 3.205 (1.222–4.563) 
Clinical cirrhosis 1.204 (1.117–1.655) 
Side effect related to ART 1.636 (1.290–2.316) 
ART, antiretroviral therapy; OR, odds ratio; CI, conﬁdence interval; HIV, human immun3.7. HBV replication and hepatitis ﬂares
The proportions of HIV/HBV co-infected subjects with detect-
able HBV-DNA and hepatitis ﬂares at different durations of ART are
shown in Table 6. There were signiﬁcant differences among
multiple groups (p = 0.0001).
3.8. Deaths and HBV-related end-stage liver diseases
Nineteen out of 78 HIV/HBV co-infected subjects (24.4%) died
during the follow-up period, compared with 28 out of 550 HIV
mono-infected subjects (5.1%). The 19 cases died at a median of
52.4 months post-ART (IQR 48.9–56.0 months); in comparison, the
28 cases died at a median of 58.0 months post-ART (IQR 56.3–59.6
months). A more rapid occurrence of death was observed in HIV/
HBV co-infected subjects (p = 0.0001, Figure 2).
Among the HIV/HBV co-infected subjects, 11 died of liver
cirrhosis, three died of hepatocellular carcinoma (HCC), two died of
fulminant hepatitis, two died of AIDS, and one died of tuberculosis
(TB). HBV-related mortality was the most common cause of death
(16/19, 84.2%).Multivariate analysis
p-Value OR (95% CI) p-Value
0.867 - -
0.430 - -
0.995 - -
0.002 2.362 (1.522–3.542) 0.001
0.021 2.323 (1.284–3.503) 0.011
0.032 1.497 (1.188–2.783) 0.024
0.012 2.704 (1.890–2.961) 0.031
0.038 1.378 (1.203–1.664) 0.023
0.003 1.270 (1.113–1.729) 0.013
odeﬁciency virus; HBV, hepatitis B virus.
Table 3
Median CD4 cell count at different times after the initiation of ART, by HBV infection group
Duration of ART (months) HIV mono-infected HIV/HBV co-infected p-Value
CD4 tested, n Cells/ml, median (IQR) CD4 tested, n Cells/ml, median (IQR)
3–6 546 195 (80–263) 78 191 (78–260) 0.958
7–12 546 227 (127–302) 78 264 (133–300) 0.411
13–24 483 279 (150–338) 76 317 (162–362) 0.301
25–36 434 287 (214–377) 70 307 (220–385) 0.639
37–48 385 333 (246–380) 58 280 (210–354) 0.041
49–60 357 363 (296–421) 50 304 (218–325) 0.037
ART, antiretroviral therapy; HBV, hepatitis B virus; HIV, human immunodeﬁciency virus; IQR, interquartile range.
Table 4
Comparison of HIV-RNA positive rates after the initiation of ART, by HBV infection group
Duration of ART (months) HIV mono-infected HIV/HBV co-infected p-Value
Number tested Number with detectable HIV-RNA (%) Number tested Number with detectable HIV-RNA (%)
3–12 546 108 (19.8%) 78 13 (16.7%) 0.515
13–24 483 95 (19.7%) 76 13 (17.1%) 0.599
25–36 434 98 (22.6%) 70 19 (27.1%) 0.401
37–48 385 81 (21.0%) 58 23 (39.7%) 0.002
49–60 357 84 (23.5%) 50 21 (42.0%) 0.005
HIV, human immunodeﬁciency virus; ART, antiretroviral therapy; HBV, hepatitis B virus.
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In this Chinese ART center, HBV co-infection did not affect the
early response to ART. However, the immune and virological
responses to ART at 48 months post-ART were poorer in HIV/HBV
co-infected subjects. Furthermore, we demonstrated that HBV co-
infection increased the risk of ART-related hepatotoxicity, and HBV-
related mortality was the most common cause of death after ART.
The current guidelines for the treatment of HIV/HBV co-
infected persons recommend that patients who need treatment for
HBV receive ART in advance.13 Even so, the baseline levels of CD4
and HIV-RNA did not differ between mono- and co-infected
patients in this study. The potential reason for this is that although
HBV is highly endemic in China, HBV testing has not been carried
out widely. Most individuals in this study did not know their HBV
infection status until they started ART.
Other studies have assessed the impact of hepatitis B on the
response to ART and have reported different ﬁndings.5,8,9 CD4
recovery was poorer and the HIV-RNA levels were higher in
patients with CHB at 48 months post-ART. The results of this study
do not completely disagree with those of other studies, because
similar results were found for the same duration of ART.
Differences in results may be attributable to the different ART
regimens, the duration of ART, the proportion of hepatitis B e
antigen (HBeAg), and HBV disease characteristics. The ﬁnding that
liver damage was more common in the HIV/HBV co-infected group
may be accounted for by the greater virological failure in co-
infected patients after 48 months, because adjustments toTable 5
Proportion of patients who experienced a hepatotoxicity event after the initiation of A
HIV mon
LFT tested, sum number  frequency 5880 
Sum number  frequency with elevated ALT or AST (%) 546 (9.
Hepatotoxicity gradea
1 343 (5.
2 189 (3.
3 11 (0.
4 3 (0.
ART, antiretroviral therapy; HBV, hepatitis B virus; HIV, human immunodeﬁciency
aminotransferase; ULN, upper limit of normal.
a Hepatotoxicity grade 1: 1  ULN < ALT or AST  2.5  ULN; hepatotoxicity grade 2: 
10  ULN; hepatotoxicity grade 4: ALT or AST > 10  ULN.medication or withdrawal related to liver damage can decrease
compliance.
CHB is associated with liver enzyme level elevations in ART
recipients.14,15 The high rate of hepatotoxicity in those with HBV
co-infection is a challenge during ART. The usage of NVP has been
found to be a contributing factor. Another explanation relates to
immune recovery inﬂammatory syndrome. A further possible
explanation is that some HBV co-infected patients develop 3TC-
resistant hepatitis B due to long-term 3TC monotherapy.16,17
According to some reports, d4T can induce abnormal liver tests
both in mice18 and in adult Erythrocebus patas monkeys.19
Similarly, multivariate logistic regression deﬁned the use of d4T
(odds ratio 7.1, 95% conﬁdence interval 1.0–54.5, p = 0.05) as an
independent risk factor for aggravation of hepatitis in HIV/HCV co-
infected patients.20 The use of d4T was common in China until
August 2013; 56.9% of subjects in this study received d4T-based
ART. The high usage of d4T may have been another cause of the
liver toxicity seen in this study.
Co-infection with HIV and HBV may lead to accelerated hepatic
disease progression with higher rates of liver cirrhosis and liver-
related mortality compared with HBV mono-infection. In this
study, HBV-related mortality accounted for 84.2% of deaths in the
HIV/HBV co-infected patients. Despite the advent of ART, liver-
related mortality has become the leading cause of non-AIDS-
related death in HIV-infected patients in China, whereas cancer has
become the ﬁrst cause of mortality in Western countries.21,22 The
fact that HBV infection is serious in China may account for this
difference.RT, by HBV infection group
o-infected HIV/HBV co-infected p-Value
946 -
3%) 212 (22.4%) 0.0001
8%) 120 (12.7%) 0.0001
2%) 66 (7.0%) 0.0001
2%) 16 (1.7%) 0.0001
05%) 10 (1.1%) 0.0001
 virus; LFT, liver function tests; ALT alanine aminotransferase; AST, aspartate
2.5  ULN < ALT or AST  5  ULN; hepatotoxicity grade 3: 5  ULN <ALT or AST 
Figure 2. Survival probability in HIV/HBV co-infected patients and HIV mono-infected patients who initiated ART. Green line: patients without HBV infection; blue line:
patients with HBV co-infection.
Table 6
Comparison of the proportion of HIV/HBV co-infected subjects with detectable HBV-DNA and hepatitis ﬂares with different durations of ART
Duration of ART (months) Number tested Number with detectable HBV-DNA (%)a Number with hepatitis ﬂares (%)b
3–12 78 4 (5.1) 4 (5.1)
13–24 76 7 (9.2) 3 (3.9)
25–36 70 13 (18.6) 1 (1.4)
37–48 58 20 (34.5) 6 (10.3)
49–60 50 20 (40.0) 2 (4.0)
HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; ART, antiretroviral therapy.
a p = 0.0001.
b p = 0.0001.
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TDF was only used as a second-line regimen in China before 2012,
none of the patients in this study received TDF therapy. Second,
since NVP was more widely used than EFV due to its cheaper price
in China, we were unable to compare the differences between NVP
and EFV on hepatotoxicity during ART. Third, HBsAg alone is
insufﬁcient to predict hepatotoxicity. Fourth, data on alcohol
intake, body mass index, TB therapy, and the use of herbal
medications, which are important to identify the etiology of
alanine aminotransferase (ALT) elevations, were incomplete.
In summary, this study demonstrates that HBV can affect the
long-term ability to respond to ART in terms of HIV-RNA
suppression and immunological recovery at 48 months post-
ART. Of note, the occurrences of hepatotoxicity and mortality were
high among HBV co-infected patients. Our data suggest the careful
use of D-drugs and NVP, still common in resource-limited
countries, in HBV co-infected patients. Moreover, for HIV/HBV
co-infected patients, it is important to use ART that includes two
agents with activity against both HIV and HBV.
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